Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category.Don't Miss out on Research Tools:Discover the ...

Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...

Neurogene (NASDAQ:NGNE) just reported results for the first quarter of 2024. Neurogene reported earnings per share of -$1.00. This was above the analyst estimate for EPS of -$1.13. The company did ...

Neurogene's stock {$NGNE} fell 35% in post-market trading on Monday after a Rett syndrome patient who received a high dose of ...

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the pharmaceutical company’s shares to drop massively in after-hours trading ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday ...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases ...